Cargando…

Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome

Background: Serum carcinoembryonic antigen (CEA), a classic tumour marker, is widely used in lung cancer in clinical practice. Nevertheless, few studies have elucidated the influence of dynamic changes in CEA in the perioperative phases, as a prognostic indicator, on lung cancer prognosis. Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Zonglin, Cao, Shoubo, Li, Jianhua, Hu, Nan, Gong, Yinghui, Wang, Linduo, Jin, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578711/
https://www.ncbi.nlm.nih.gov/pubmed/34778369
http://dx.doi.org/10.3389/fmolb.2021.686313
_version_ 1784596291132588032
author Jiao, Zonglin
Cao, Shoubo
Li, Jianhua
Hu, Nan
Gong, Yinghui
Wang, Linduo
Jin, Shi
author_facet Jiao, Zonglin
Cao, Shoubo
Li, Jianhua
Hu, Nan
Gong, Yinghui
Wang, Linduo
Jin, Shi
author_sort Jiao, Zonglin
collection PubMed
description Background: Serum carcinoembryonic antigen (CEA), a classic tumour marker, is widely used in lung cancer in clinical practice. Nevertheless, few studies have elucidated the influence of dynamic changes in CEA in the perioperative phases, as a prognostic indicator, on lung cancer prognosis. Methods: This retrospective cohort analysis included consecutive patients with stage I-III lung cancer who underwent curative resection between December 2010 and December 2014. The patients were grouped into three cohorts: group A included patients with normal preoperative CEA, group B included patients with elevated preoperative CEA but normal postoperative CEA, and group C included patients with elevated preoperative and postoperative CEA. Five-year overall survival (OS) was estimated by Kaplan-Meier analysis (log-rank test). Multivariate analyses were performed with Cox proportional hazard regression. Results: A total of 1662 patients with stage I-III lung cancer were enrolled in our study. Patients with normal preoperative CEA had 15.9 and 20.1% better 3- and 5-year OS rates than the cohort with elevated preoperative CEA (p < 0.001). Furthermore, group C had 36.0 and 26.6% lower 5-year OS rates (n = 74, 32.4%) than group A (n = 1188, 68.4%) and group B (n = 139, 59.0%) (p < 0.001). Group B had poorer OS than group A (p = 0.016). For patients with different pathological TNM stages, subgroup analyses showed that group C had the shortest OS in stages I and II (p < 0.05), and patients with a post-preoperative CEA increment had poorer OS than those without an increment (p = 0.029). Multivariate analyses suggested that group C (HR = 2.0, 95% CI, 1.5–2.7, p < 0.001) rather than the group with normalized postoperative CEA (HR = 1.2, 95% CI, 0.9–1.5, p = 0.270) was an independent prognostic factor. In subgroup analysis of adenocarcinoma (ADC), survival analyses suggested that group C predicted a worse prognosis. Multivariate analysis of ADC indicated that group C was an independent adverse prognostic factor (HR = 1.9, 95% CI, 1.4–2.7, p < 0.001). Conclusions: Combined elevated preoperative and postoperative CEA is an independent adverse prognostic factor for stage I-III lung adenocarcinoma. Additionally, routine perioperative detection of serum CEA can yield valuable prognostic information for patients after lung cancer surgery.
format Online
Article
Text
id pubmed-8578711
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85787112021-11-11 Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome Jiao, Zonglin Cao, Shoubo Li, Jianhua Hu, Nan Gong, Yinghui Wang, Linduo Jin, Shi Front Mol Biosci Molecular Biosciences Background: Serum carcinoembryonic antigen (CEA), a classic tumour marker, is widely used in lung cancer in clinical practice. Nevertheless, few studies have elucidated the influence of dynamic changes in CEA in the perioperative phases, as a prognostic indicator, on lung cancer prognosis. Methods: This retrospective cohort analysis included consecutive patients with stage I-III lung cancer who underwent curative resection between December 2010 and December 2014. The patients were grouped into three cohorts: group A included patients with normal preoperative CEA, group B included patients with elevated preoperative CEA but normal postoperative CEA, and group C included patients with elevated preoperative and postoperative CEA. Five-year overall survival (OS) was estimated by Kaplan-Meier analysis (log-rank test). Multivariate analyses were performed with Cox proportional hazard regression. Results: A total of 1662 patients with stage I-III lung cancer were enrolled in our study. Patients with normal preoperative CEA had 15.9 and 20.1% better 3- and 5-year OS rates than the cohort with elevated preoperative CEA (p < 0.001). Furthermore, group C had 36.0 and 26.6% lower 5-year OS rates (n = 74, 32.4%) than group A (n = 1188, 68.4%) and group B (n = 139, 59.0%) (p < 0.001). Group B had poorer OS than group A (p = 0.016). For patients with different pathological TNM stages, subgroup analyses showed that group C had the shortest OS in stages I and II (p < 0.05), and patients with a post-preoperative CEA increment had poorer OS than those without an increment (p = 0.029). Multivariate analyses suggested that group C (HR = 2.0, 95% CI, 1.5–2.7, p < 0.001) rather than the group with normalized postoperative CEA (HR = 1.2, 95% CI, 0.9–1.5, p = 0.270) was an independent prognostic factor. In subgroup analysis of adenocarcinoma (ADC), survival analyses suggested that group C predicted a worse prognosis. Multivariate analysis of ADC indicated that group C was an independent adverse prognostic factor (HR = 1.9, 95% CI, 1.4–2.7, p < 0.001). Conclusions: Combined elevated preoperative and postoperative CEA is an independent adverse prognostic factor for stage I-III lung adenocarcinoma. Additionally, routine perioperative detection of serum CEA can yield valuable prognostic information for patients after lung cancer surgery. Frontiers Media S.A. 2021-10-27 /pmc/articles/PMC8578711/ /pubmed/34778369 http://dx.doi.org/10.3389/fmolb.2021.686313 Text en Copyright © 2021 Jiao, Cao, Li, Hu, Gong, Wang and Jin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Jiao, Zonglin
Cao, Shoubo
Li, Jianhua
Hu, Nan
Gong, Yinghui
Wang, Linduo
Jin, Shi
Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome
title Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome
title_full Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome
title_fullStr Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome
title_full_unstemmed Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome
title_short Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome
title_sort clinical associations of preoperative and postoperative serum cea and lung cancer outcome
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578711/
https://www.ncbi.nlm.nih.gov/pubmed/34778369
http://dx.doi.org/10.3389/fmolb.2021.686313
work_keys_str_mv AT jiaozonglin clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome
AT caoshoubo clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome
AT lijianhua clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome
AT hunan clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome
AT gongyinghui clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome
AT wanglinduo clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome
AT jinshi clinicalassociationsofpreoperativeandpostoperativeserumceaandlungcanceroutcome